Human Cannabinoid Receptor Interacting Protein 1 (CNRIP1) Protein

Product specifications

Proteins and Peptides

Cannabinoid Receptor Interacting Protein 1 (CNRIP1)

E. coli

Human

Unconjugated

Molecular Weight: Calculated MW: 18.7 kDa
Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Gln34-Leu164
Tag: N-terminal His tag

Recombinant

> 95%

10 µg

50 µg

100 µg

200 µg

500 µg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Shipped within 5-7 working days.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

Q96F85

CNRIP1,CRIP1,CRIP-1,C2orf32

Protein CNRIP1

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

Cannabinoid receptor interacting protein 1 (CNRIP1) is an intracellular protein that interacts with cannabinoid receptors, specifically CB1 (cannabinoid receptor type 1), which is primarily found in the central nervous system and plays a pivotal role in modulating various physiological processes, including pain perception, appetite, and mood. CNRIP1 is thought to be involved in regulating the signaling pathways of CB1, modulating its activity, and potentially impacting receptor desensitization or internalization. Through its interaction with CB1, CNRIP1 indirectly participates in the endocannabinoid system, which maintains homeostasis in processes such as synaptic transmission, immune response, and neuroprotection. Beyond the nervous system, CNRIP1 may also influence metabolic and energy balance functions, as CB1 receptors are expressed in peripheral tissues like adipose tissue, liver, and skeletal muscle. Aberrant expression or function of CNRIP1 has been implicated in pathological conditions such as obesity, neurodegenerative disorders, and substance use disorders, highlighting its potential as a target for therapeutic interventions. CNRIP1 continues to be an area of active research, with a focus on elucidating its precise molecular mechanisms and broader implications in cannabinoid receptor-mediated pathways.

Related Products

CNRIP1 antibody

Isoform 1 suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. Isoform 2 does not have this effect.

Ver Producto

Recombinant Human CNRIP1

Ver Producto

CB1 Cannabinoid Receptor-Interacting Protein 1 (CNRP1) Antibody

This gene encodes a G-protein coupled receptor which interacts with the C-terminal tail of cannabinoid receptor 1. This receptor plays a role in synaptic plasticity, analgesia, appetite, and neuroprotection. Two transcript variants encoding different isoforms have been described for this gene.

Ver Producto